Vanguard Group
KLRS

Vanguard Group’s Kalaris Therapeutics KLRS Stock Holding History

Vanguard Group’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.47M Buy
292,790
+89,739
+44% +$574K ﹤0.01% 3492
2025
Q3 		$1.17M Buy
203,051
+73,212
+56% +$242K ﹤0.01% 3740
2025
Q2 		$347K Buy
129,839
+14,753
+13% +$66.6K ﹤0.01% 3996
2025
Q1 		$924K Sell
115,086
-1
-0% -$10 ﹤0.01% 3735
2024
Q4 		$1.11M Hold
115,087
– – ﹤0.01% 3730
2024
Q3 		$2.14M Hold
115,087
– – ﹤0.01% 3538
2024
Q2 		$1.91M Sell
115,087
-11,976
-9% -$211K ﹤0.01% 3567
2024
Q1 		$2.21M Sell
127,063
-702
-0.5% -$11.5K ﹤0.01% 3560
2023
Q4 		$2M Buy
127,765
+8,133
+7% +$321K ﹤0.01% 3605
2023
Q3 		$5.92M Buy
119,632
+2,592
+2% +$177K ﹤0.01% 3176
2023
Q2 		$9.15M Sell
117,040
-12,213
-9% -$1.16M ﹤0.01% 2995
2023
Q1 		$11.7M Buy
129,253
+952
+0.7% +$121K ﹤0.01% 2853
2022
Q4 		$15.1M Buy
128,301
+1,727
+1% +$293K ﹤0.01% 2761
2022
Q3 		$23M Buy
126,574
+37,530
+42% +$5.85M ﹤0.01% 2568
2022
Q2 		$7.99M Sell
89,044
-27,404
-24% -$2.87M ﹤0.01% 3109
2022
Q1 		$18.1M Sell
116,448
-5,012
-4% -$1,000K ﹤0.01% 2829
2021
Q4 		$36.1M Sell
121,460
-55
-0% -$25.5K ﹤0.01% 2530
2021
Q3 		$70M Buy
121,515
+19,239
+19% +$8.91M ﹤0.01% 2174
2021
Q2 		$46.4M Buy
102,276
+7,256
+8% +$3.75M ﹤0.01% 2416
2021
Q1 		$51.1M Buy
95,020
+33,752
+55% +$28.4M ﹤0.01% 2304
2020
Q4 		$54.2M Buy
61,268
+2,327
+4% +$1.79M ﹤0.01% 2154
2020
Q3 		$37.3M Buy
+58,941
New +$40.3M ﹤0.01% 2160

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
WT
WHI Trust Chicago, Illinois $133M AUM

Vanguard Group's KLRS Position: Q4 2025 in Review

Vanguard Group increased its Kalaris Therapeutics (KLRS) stake by 44% in Q4 2025, buying an estimated $574K and bringing the position to 292,790 shares worth $2.47M. The position accounts for ﹤0.01% of the portfolio, ranked #3492.

Vanguard Group first reported a position in KLRS in Q3 2020 and has held it in 22 quarters since. The position peaked at $70M in Q3 2021. 51 funds tracked by Wall St. Rank hold KLRS as of Q4 2025.

  • Vanguard Group held 292,790 shares of Kalaris Therapeutics worth $2.47M as of Q4 2025.
  • Vanguard Group bought 89,739 Kalaris Therapeutics shares in Q4 2025, an estimated $574K.
  • Kalaris Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3492 holding.
  • Vanguard Group first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Vanguard Group's Kalaris Therapeutics position peaked at $70M in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.